• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$2.07 -$0.27 (-11.54%)

REAL-TIME: Last trade at

Novogen Limited (ADR)

NASDAQ:NVGN

Jump to this page for:

Related Resources

Novogen Limited falls 14.1%

5/25/2012 by Theflyonthewall.com

Marshall Edwards receives $4M subscription from Novogen

5/8/2012 by San Diego Daily Transcript - San Diego CA

Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering

5/8/2012 by StockWatch

Marshall Edwards receives $4M subscription from Novogen in rights offering

5/8/2012 by Theflyonthewall.com

Oppenheimer Funds reports 11.31% passive stake in Novogen Limited

4/9/2012 by Theflyonthewall.com

Organovo's 3D Bioprinting: A Win For Pharmaceuticals?

3/12/2012 by Seeking Alpha

As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards

1/4/2012 by PR Newswire

Novogen Limited lowers stake in Marshall Edwards to 68.5% from 78.2%

10/5/2011 by Theflyonthewall.com

Marshall Edwards (MHSL) Surges On FDA Approves IND Application; Novogen (NVGN) Bounces

8/16/2011 by StreetInsider.com

NASDAQ Winners July 27th: Marshall Edwards, Novogen, Acxiom, IAC

7/28/2011 by Benzinga

Asian Activities Report for July 28, 2011: Novogen Limited (ASX:NRT) Announce Results of Pre-Clinical Studies in Chemotherapy-Resistant Ovarian Cancer Stem Cells

7/27/2011 by StockWatch

Novogen Receives Nasdaq Notice of Non-Compliance

7/25/2011 by Benzinga

Novogen Ltd. (ADR) is Today's Focus Stock on MicroStockProfit.com

3/29/2011 by StockWatch

Novogen Ltd. (ADR) is Today's Focus Stock on MicroStockProfit.com

3/29/2011 by GlobeNewswire

Novogen Limited (NVGN) Surges Higher On Heavy Volume

3/28/2011 by StreetInsider.com

Marshall Edwards announces publication of Ph 2 clinical trial results

3/22/2011 by Theflyonthewall.com

Novogen Accepts $4M in Stock from Marshall Edwards Subsidiary for Isoflavone IP

12/22/2010 by Genetic Engineering News

Novogen and Marshall Edwards sign asset purchase agreement

12/22/2010 by Theflyonthewall.com

Novogen and Marshall Edwards Sign Asset Purchase Agreement

12/21/2010 by StockHouse

First Fully Bioprinted Blood Vessels

12/9/2010 by PharmiWeb.com - UK

First Fully Bioprinted Blood Vessels

12/8/2010 by Business Wire

Market Report, "Novogen Limited - Product Pipeline Review - Q4 2010", published

11/28/2010 by PR-inside - Austria

Marshall Edwards to acquire Novogen's intellectual property portfolio

9/8/2010 by Theflyonthewall.com

Marshall Edwards Reaches Agreement in Principle to Acquire Intellectual Property Portfolio From Novogen

9/8/2010 by PR Newswire

Marshall Edwards to Host Conference Call on September 8, 2010

8/31/2010 by PR Newswire

Marshall Edwards Appoints Oncologist Christine White to Board of Directors

8/10/2010 by PR Newswire

Novogen Limited Receives Nasdaq Notice

7/23/2010 by Pharmaceutical Processing

Novogen Limited receives Nasdaq notice

7/23/2010 by Theflyonthewall.com

Novogen Limited Restructures Australian Management Team and Marshall Edwards, Inc. Appoints CFO

6/18/2010 by Pharm Country

Marshall Edwards (MSHL) Appoints Thomas Zech as CFO; Other Changes Announced

6/18/2010 by StreetInsider.com

Marshall Edwards Inc., Announces Final Results From Halted Phase 3 Clinical Trial Of Phenoxodiol

6/1/2010 by Pharmaceutical Online